ACUT
Price
$0.98
Change
+$0.09 (+10.11%)
Updated
Jun 27 closing price
Capitalization
15.75M
VRNA
Price
$93.82
Change
-$0.58 (-0.61%)
Updated
Jun 27 closing price
Capitalization
7.99B
31 days until earnings call
Interact to see
Advertisement

ACUT vs VRNA

Header iconACUT vs VRNA Comparison
Open Charts ACUT vs VRNABanner chart's image
Accustem Sciences
Price$0.98
Change+$0.09 (+10.11%)
Volume$459
Capitalization15.75M
Verona Pharma
Price$93.82
Change-$0.58 (-0.61%)
Volume$951.42K
Capitalization7.99B
ACUT vs VRNA Comparison Chart in %
Loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. VRNA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and VRNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ACUT: $0.98 vs. VRNA: $93.82)
Brand notoriety: ACUT and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 15% vs. VRNA: 67%
Market capitalization -- ACUT: $15.75M vs. VRNA: $7.99B
ACUT [@Biotechnology] is valued at $15.75M. VRNA’s [@Biotechnology] market capitalization is $7.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACUT and VRNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACUT’s TA Score shows that 5 TA indicator(s) are bullish while VRNA’s TA Score has 2 bullish TA indicator(s).

  • ACUT’s TA Score: 5 bullish, 3 bearish.
  • VRNA’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ACUT is a better buy in the short-term than VRNA.

Price Growth

ACUT (@Biotechnology) experienced а +8.77% price change this week, while VRNA (@Biotechnology) price change was -0.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

VRNA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($7.99B) has a higher market cap than ACUT($15.8M). ACUT YTD gains are higher at: 118.750 vs. VRNA (102.024). ACUT has higher annual earnings (EBITDA): -1.42M vs. VRNA (-121.41M). VRNA has more cash in the bank: 401M vs. ACUT (36.4K). ACUT has less debt than VRNA: ACUT (57.6K) vs VRNA (244M). VRNA has higher revenues than ACUT: VRNA (119M) vs ACUT (0).
ACUTVRNAACUT / VRNA
Capitalization15.8M7.99B0%
EBITDA-1.42M-121.41M1%
Gain YTD118.750102.024116%
P/E RatioN/AN/A-
Revenue0119M-
Total Cash36.4K401M0%
Total Debt57.6K244M0%
FUNDAMENTALS RATINGS
VRNA: Fundamental Ratings
VRNA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
PROFIT vs RISK RATING
1..100
2
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACUTVRNA
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
90%
N/A
MACD
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
79%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VCIGF4.000.38
+10.50%
Vitreous Glass Inc.
NCRBF30.00N/A
N/A
Nippon Carbon Co., Ltd.
NDGPY8.30N/A
N/A
Nine Dragons Paper Holdings Ltd.
BMYMP801.01N/A
N/A
Bristol-Myers Squibb Co.
SOMLY8.89-0.06
-0.67%
Secom Co., Ltd.

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and LGVN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and LGVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
+10.61%
LGVN - ACUT
30%
Poorly correlated
+1.54%
OKYO - ACUT
28%
Poorly correlated
+1.44%
IGMS - ACUT
21%
Poorly correlated
N/A
APVO - ACUT
20%
Poorly correlated
-4.64%
VRNA - ACUT
20%
Poorly correlated
-0.61%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with TERN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then TERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
-0.61%
TERN - VRNA
40%
Loosely correlated
-4.25%
ARCT - VRNA
40%
Loosely correlated
-7.49%
ROIV - VRNA
39%
Loosely correlated
-1.81%
CRNX - VRNA
39%
Loosely correlated
-0.10%
LGND - VRNA
39%
Loosely correlated
-1.33%
More